PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4+ T cell function

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Ghonim, Mohamed A ^a,b   Pyakurel, Kusma ^a   Ibba, Salome V ^a   Al Khami, Amir A ^a,c   Wang, Jeffrey ^a   Rodriguez, Paulo ^a   Rady, Hamada F ^d   El Bahrawy, Ali H ^a   Lammi, Matthew R ^d   Mansy, Moselhy S ^b   Al Ghareeb, Kamel ^b   Ramsay, Alistair ^d   Ochoa, Augusto ^a   Naura, Amarjit S ^a,e   Boulares, A Hamid ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Cairo University   (Egypt)

^c Tanta University   (Egypt)

^d LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e PANJAB UNIVERSITY   (India)

Author keywords

Adoptive transfer; Allergen induced eosinophilia; Allergen specific IgE; Olaparib (AZD2281); PARP inhibition; Th2 cytokines

Indexed keywords

CD28 ANTIGEN; COLONY STIMULATING FACTOR 1; EOTAXIN; GAMMA INTERFERON; IMMUNOGLOBULIN E; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLAPARIB; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; CYTOKINE; LEUKOCYTE ANTIGEN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OVALBUMIN; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE; T BOX TRANSCRIPTION FACTOR; T-BOX TRANSCRIPTION FACTOR TBX21;

ALLERGIC AIRWAY INFLAMMATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTHMA; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; EX VIVO STUDY; GATA 3 GENE; GENE TARGETING; IFN GAMMA GENE; IL4 GENE; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; LYMPHOCYTE SUBPOPULATION; MOUSE; MUCUS SECRETION; NONHUMAN; T BET GENE; TH1 CELL; TH2 CELL; ADOPTIVE TRANSFER; ANIMAL; BIOSYNTHESIS; BRONCHIAL HYPERREACTIVITY; C57BL MOUSE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; EOSINOPHILIA; GENE INACTIVATION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MUCUS; SPLEEN;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD; ASTHMA; BRONCHIAL HYPERREACTIVITY; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DISEASE MODELS, ANIMAL; EOSINOPHILIA; GATA3 TRANSCRIPTION FACTOR; GENE KNOCKOUT TECHNIQUES; HUMANS; IMMUNOGLOBULIN E; MICE, INBRED C57BL; MUCUS; OVALBUMIN; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES; SPLEEN; T-BOX DOMAIN PROTEINS; TH1 CELLS; TH2 CELLS;

EID: 84937044948     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0583-0     Document Type: Article

References (33)

1. Yoo Y, Perzanowski MS (2014) Allergic sensitization and the environment: latest update. Curr Allergy Asthma Rep 14:465
2. Barnes CB, Ulrik CS (2015) Asthma and adherence to inhaled corticosteroids: current status and future perspectives. Respir Care 60(3):455-468
3. Barnes PJ (2011) Biochemical basis of asthma therapy. J Biol Chem 286:32899-32905
4. Boulares AH, Zoltoski AJ, Sherif ZA, Jolly P, Massaro D, Smulson ME (2003) Gene knockout or pharmacological inhibition of poly(ADP-ribose) polymerase-1 prevents lung inflammation in a murine model of asthma. Am J Respir Cell Mol Biol 28:322-329
5. Oumouna M, Datta R, Oumouna-Benachour K, Suzuki Y, Hans C, Matthews K et al (2006) Poly(ADP-ribose) polymerase-1 inhibition prevents eosinophil recruitment by modulating Th2 cytokines in a murine model of allergic airway inflammation: a potential specific effect on IL-5. J Immunol 177:6489-6496
6. Naura AS, Hans CP, Zerfaoui M, You D, Cormier SA, Oumouna M et al (2008) Post-allergen challenge inhibition of poly(ADP-ribose) polymerase harbors therapeutic potential for treatment of allergic airway inflammation. Clin Exp Allergy 38:839-846
7. Naura AS, Datta R, Hans CP, Zerfaoui M, Rezk BM, Errami Y et al (2009) Reciprocal regulation of iNOS and PARP-1 during allergen-induced eosinophilia. Eur Respir J 33:252-262
8. Datta R, Naura AS, Zerfaoui M, Errami Y, Oumouna M, Kim H et al (2011) PARP-1 deficiency blocks IL-5 expression through calpain-dependent degradation of STAT-6 in a murine asthma model. Allergy 66:853-861
9. Virag L, Bai P, Bak I, Pacher P, Mabley JG, Liaudet L et al (2004) Effects of poly(ADP-ribose) polymerase inhibition on inflammatory cell migration in a murine model of asthma. Med Sci Monit 10:BR77-BR83
10. Suzuki Y, Masini E, Mazzocca C, Cuzzocrea S, Ciampa A, Suzuki H et al (2004) Inhibition of poly(ADP-ribose) polymerase prevents allergen-induced asthma-like reaction in sensitized Guinea pigs. J Pharmacol Exp Ther 311:1241-1248
11. Virag L (2005) Poly(ADP-ribosyl)ation in asthma and other lung diseases. Pharmacol Res 52:83-92
12. Tezcan G, Gurel CB, Tutluoglu B, Onaran I, Kanigur-Sultuybek G (2009) The Ala allele at Val762Ala polymorphism in poly(ADP-ribose) polymerase-1 (PARP-1) gene is associated with a decreased risk of asthma in a Turkish population. J Asthma 46:371-374
13. Lucarini L, Pini A, Gerace E, Pellicciari R, Masini E, Moroni F (2014) Poly(ADP-ribose) polymerase inhibition with HYDAMTIQ reduces allergen-induced asthma-like reaction, bronchial hyper-reactivity and airway remodelling. J Cell Mol Med 18:468-479
14. Smulson ME, Simbulan-Rosenthal CM, Boulares AH, Yakovlev A, Stoica B, Iyer S et al (2000) Roles of poly(ADP-ribosyl)ation and PARP in apoptosis, DNA repair, genomic stability and functions of p53 and E2F-1. Adv Enzyme Regul 40:183-215
15. Zerfaoui M, Suzuki Y, Naura AS, Hans CP, Nichols C, Boulares AH (2008) Nuclear translocation of p65 NF-kappaB is sufficient for VCAM-1, but not ICAM-1, expression in TNF-stimulated smooth muscle cells: Differential requirement for PARP-1 expression and interaction. Cell Signal 20:186-194
16. Zerfaoui M, Naura AS, Errami Y, Hans CP, Rezk BM, Park J et al (2009) Effects of PARP-1 deficiency on airway inflammatory cell recruitment in response to LPS or TNF: differential effects on CXCR2 ligands and Duffy Antigen Receptor for Chemokines. J Leukoc Biol 86:1385-1392
17. Zerfaoui M, Errami Y, Naura AS, Suzuki Y, Kim H, Ju J et al (2010) Poly(ADP-ribose) polymerase-1 is a determining factor in Crm1-mediated nuclear export and retention of p65 NF-kappa B upon TLR4 stimulation. J Immunol 185:1894-1902
18. Curtin NJ, Szabo C (2013) Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol Aspects Med 34:1217-1256
19. Jelinic P, Levine DA (2014) New insights into PARP inhibitors' effect on cell cycle and homology-directed DNA damage repair. Mol Cancer Ther 13:1645-1654
20. Plummer R (2011) Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer? Breast Cancer Res 13:218
21. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M et al (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123-134
22. Naura AS, Zerfaoui M, Kim H, Abd Elmageed ZY, Rodriguez PC, Hans CP et al (2010) Requirement for inducible nitric oxide synthase in chronic allergen exposure-induced pulmonary fibrosis but not inflammation. J Immunol 185:3076-3085
23. Ghonim MA, Pyakurel K, Ju J, Rodriguez PC, Lammi MR, Davis C et al (2015) DNA-dependent protein kinase inhibition blocks asthma in mice and modulates human endothelial and CD4 T-cell function without causing severe combined immunodeficiency. J Allergy Clin Immunol 135:425-440
24. Naura AS, Kim H, Ju J, Rodriguez PC, Jordan J, Catling AD et al (2013) Minocycline blocks asthma-associated inflammation in part by interfering with the T Cell receptor-NF-kB-GATA-3-IL-4 axis without a prominent effect on PARP. J Biol Chem 288:1458-1468
25. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408
26. Kapoor K, Singla E, Sahu B, Naura AS (2015) PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice. Mol Cell Biochem 400:153-162
27. Sharma R, Sung SS, Gaskin F, Fu SM, Ju ST (2012) A novel function of IL-2: chemokine/chemoattractant/retention receptor genes induction in Th subsets for skin and lung inflammation. J Autoimmun 38:322-331
28. Zheng W, Flavell RA (1997) The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 89:587-596
29. Nasta F, Laudisi F, Sambucci M, Rosado MM, Pioli C (2010) Increased Foxp3+ regulatory T cells in poly(ADP-Ribose) polymerase-1 deficiency. J Immunol 184:3470-3477
30. Zhang P, Maruyama T, Konkel JE, Abbatiello B, Zamarron B, Wang ZQ et al (2013) PARP-1 controls immunosuppressive function of regulatory T cells by destabilizing Foxp3. PLoS One 8:e71590
31. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K et al (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12:852-861
32. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G et al (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366:1382-1392
33. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G et al (2014) Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15:852-861